Elixinol Wellness Reports Record Revenue and Margin Lift

Record Revenue and Margin Expansion Signal Growth Phase

Elixinol Wellness (ASX:EXL) has delivered a standout quarter, reporting record Q2 FY26 revenue of A$4.3 million with gross margin expanding to 45%, up from 38% in the prior corresponding period. This margin improvement outpaces sales growth, highlighting an increasingly profitable revenue mix.

Operating expenses were slashed by 23% year-on-year, with notable cuts across employee costs, distribution, and marketing. This leaner cost base has translated into disciplined cash management, with the company achieving three consecutive quarters of positive underlying operating cash flow, including a modest positive of A$0.05 million in Q2.

Strategic Reset Completed, Focus Shifts to Growth

Over the past three years, Elixinol has transformed from a US-centric CBD story into a diversified Australian health and wellness platform. The company’s management describes the heavy lifting as largely behind it, with a reset phase that included rebuilding margins, reducing costs, and restructuring capital obligations now complete.

Legacy perceptions tied to the US CBD market no longer reflect the company’s current earnings base, which is increasingly Australian and diversified. The next chapter focuses on scaling growth through national retail expansion, product innovation, and selective acquisitions.

Retail Expansion and Brand Momentum

Elixinol’s retail footprint is expanding rapidly, with The Healthy Chef brand leading the charge. Q2 revenue for The Healthy Chef reached A$1.15 million, a 20% increase year-on-year and 26% higher than the previous quarter. The brand now represents 27% of group revenue.

The rollout with Priceline has placed The Healthy Chef in approximately 410 stores as part of a staged national pharmacy expansion. This channel growth is complemented by ongoing partnerships with Coles and Metcash, underpinning broad market access.

Innovation and Market Tailwinds in Wellness Categories

Elixinol is capitalising on strong category tailwinds in functional nutrition, healthy ageing, and metabolic health. The company’s portfolio includes four core brands, The Healthy Chef, Mt Elephant, Hemp Foods Australia, and a B2B ingredients business, that collectively address consumer demand for plant-based nutrition, better-for-you indulgence, and nature-led innovation.

Emerging wellness trends, such as growing awareness of GLP-1 peptides and a shift towards everyday metabolic support, create fertile ground for Elixinol’s innovation pipeline. Existing products in protein waters and metabolic burn supplements provide a credible entry point, with plans to expand into nutritional peptides targeting sleep, muscle, and weight management.

Valuation Disconnect Points to Potential Upside

Despite operational improvements, Elixinol’s market valuation remains modest, with a market cap of A$2.9 million against last 12 months revenue of A$15.7 million and gross profit of A$6.7 million. This equates to a market cap-to-revenue multiple of just 0.18 times, suggesting the market has yet to fully price in the company’s growth potential.

Consistent execution on retail expansion, product innovation, and disciplined capital allocation could reshape investor sentiment and unlock re-rating opportunities as Elixinol transitions from reset to growth.